Edoxaban NEW
Price | $45 | $63 | $93 |
Package | 5mg | 10mg | 25mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-14 |
Product Details
Product Name: Edoxaban | CAS No.: 480449-70-5 |
Purity: 99.71% | Supply Ability: 10g |
Release date: 2024/11/14 |
Product Introduction
Bioactivity
名稱 | Edoxaban |
描述 | Edoxaban (Lixiana) (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is able to be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with K i s of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban has antithrombotic properties and is potential for thromboembolic diseases treatment [1] [2] [3]. |
體外活性 | Edoxaban (DU-176b) also inhibits rat, cynomolgus monkey and rabbit FXa with K i values of 6.90 nM, 0.715 nM and 0.457 nM, respectively [1]. Prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) of human plasma are prolonged by Edoxaban (DU-176b) in a concentration-dependent way, doubling PT and APTT at 0.256 and 0.508 μM, respectively. The double clotting time (CT2) for TT, however, was much higher (4.95 μM), reflecting its anti-thrombin activity. Thrombin-induced platelet aggregation is inhibited by a high concentration of Edoxaban (DU-176b) (IC 50 : 2.90 μM), reflecting its weak anti-thrombin activity [1]. Edoxaban is minimally metabolized (,4%) by the cytochrome P450 system (CYP3A4) and is a substrate for P-glycoprotein [2]. |
體內(nèi)活性 | Edoxaban (DU-176b; 0.5-12.5 mg/kg; oral administration; Wistar rats) inhibits thrombus formation in rat thrombosis models in a dose-dependent manner [1]. Animal Model: Wistar rats (210-240 g) with venous stasis thrombosis model [1] Dosage: 0.5 mg/kg, 2.5 mg/kg, 12.5 mg/kg Administration: Oral administration Result: Dose-dependently inhibited thrombus formation in rat thrombosis models. |
存儲條件 | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 1 mg/mL, Sonication is recommended. |
關(guān)鍵字 | Edoxaban |
相關(guān)產(chǎn)品 | AEBSF hydrochloride | Heparin sodium salt | Coumarin |
相關(guān)庫 | FDA上市及藥典收錄分子庫 | 經(jīng)典已知活性庫 | EMA 上市藥物庫 | 藥物功能重定位化合物庫 | 抑制劑庫 | FDA 上市藥物庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/100G |
VIP1Y
|
Watson Biotechnology Co.,Ltd
|
2024-09-24 | |
$1.00/1kg |
VIP2Y
|
Jinan Million Pharmaceutical Co., Ltd
|
2024-08-21 | |
$35.00/1kg |
VIP1Y
|
Henan Fengda Chemical Co., Ltd
|
2024-04-19 | |
$235.00/1Kg/Bag |
VIP4Y
|
Sinoway Industrial co., ltd.
|
2023-12-06 | |
$0.00/1kg |
VIP2Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2023-07-06 | |
$0.00/1kg |
XuZhou Magic Biotechnology Co., Ltd.
|
2023-02-20 | ||
$0.00/1KG |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2022-11-08 | |
$0.00/1KG Ton |
VIP3Y
|
Zhuhai Hairuide Bioscience and Technology Co., Ltd
|
2022-10-09 | |
$0.00/25kg |
VIP3Y
|
Changzhou Rokechem Technology Co., Ltd.
|
2022-08-19 | |
$0.00/25KG/CTN |
Hangzhou Huarong Pharm Co., Ltd.
|
2021-09-18 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY